PT  - JOURNAL ARTICLE
AU  - Rogier J. Nell
AU  - Nino V. Menger
AU  - Mieke Versluis
AU  - Gregorius P.M. Luyten
AU  - Robert M. Verdijk
AU  - Michele C. Madigan
AU  - Martine J. Jager
AU  - Pieter A. van der Velden
TI  - Involvement of mutant and wild-type <em>CYSLTR2</em> in the development and progression of uveal nevi and melanoma
AID  - 10.1101/2020.09.16.20191791
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.16.20191791
4099  - http://medrxiv.org/content/early/2020/09/18/2020.09.16.20191791.short
4100  - http://medrxiv.org/content/early/2020/09/18/2020.09.16.20191791.full
AB  - Background Activating Gαq signalling mutations are considered an early event in the development of uveal melanoma. Whereas most tumours harbour a mutation in GNAQ or GNA11, CYSLTR2 (encoding G-protein coupled receptor CysLT2R) forms a rare alternative. The role of wild-type CysLT2R in uveal melanoma remains unknown.Methods We performed a digital PCR-based molecular analysis of benign choroidal nevi and primary uveal melanomas. Publicly available bulk and single cell sequencing data were mined to further study wild-type and mutant CYSLTR2.Results 1/16 nevi and 2/120 melanomas carried the CYSLTR2 mutation. The mutation was subclonal in the nevus, while being clonal in both melanomas. In the melanomas, secondary, subclonal CYSLTR2 alterations shifted the allelic balance towards the mutant. The resulting genetic heterogeneity was confirmed in distinct areas of both tumours. At the RNA level, further silencing of wild-type and preferential expression of mutant CYSLTR2 was identified, which was also observed in 2/3 CYSLTR2 mutant melanomas from the TCGA cohort. In CYSLTR2 wild-type melanomas, high expression of CYSLTR2 originated from melanoma cells and correlated to tumour inflammation.Conclusions Our findings suggest that CYSLTR2 is involved in both early and late development of uveal melanoma. Whereas the CYSLTR2 p.L129Q mutation is likely to be the initiating oncogenic event, various mechanisms further increase the mutant allele abundance during tumour progression. This makes mutant CysLT2R an attractive therapeutic target in uveal melanoma. In GNAQ, GNA11 and PLCB4 mutant melanomas, expression of wild-type CYSLTR2 possibly facilitates an interaction with immune cells in the microenvironment and may also have therapeutic potential.Competing Interest StatementThe authors have declared no competing interest.Funding StatementRJN is supported by the European Union's Horizon 2020 research and innovation program under grant agreement No 667787 (UM Cure 2020 project). MCM is supported by the Sydney Eye Hospital Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:16 choroidal nevi were dissected from 13 formalin-fixed post-mortem human donor eyes, with consent from Lions NSW Eye Bank and approval from the University of Sydney and University of New South Wales Human Research Ethics Committee (see also Vader et al. GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi. Br J Cancer. 2017;117(6):884-7). 120 fresh-frozen tumour samples, obtained from primary uveal melanomas treated by enucleation, were available from the Biobank of the Department of Ophthalmology, Leiden University Medical Center (LUMC). All patient samples were collected with informed consent and this study was approved by the LUMC Biobank Committee and Medisch Ethische Toetsingscommissie under no. B14.003/DH/sh and B20.026.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data sets analysed during the current study are available via the Broad GDAC Firehose, NCI Genomic Data Commons data portal (TCGA Uveal Melanoma data set) and Gene Expression Omnibus repository (Durante et al. single cell RNA-data set, GSE139829). https://gdac.broadinstitute.org) https://portal.gdc.cancer.gov https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139829